Pre-transplant serum level of CXCL9 as a biomarker of acute rejection and graft failure risk in kidney transplantation

Transplant International

Volumn 23, Issue 5, 2010, Pages 461-462

  Brouard, Sophie ^a,b,c   Soulillou, Jean Paul ^a,b,c  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; CXCL9 PROTEIN, HUMAN; LIGAND;

BIOPSY; CELL MIGRATION; CHEMOTAXIS; CYTOTOXIC T LYMPHOCYTE; DECISION MAKING; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NONHUMAN; NOTE; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME; ANIMAL; BLOOD; METABOLISM; MOUSE; PREOPERATIVE PERIOD; PROCEDURES; RISK;

ANIMALS; BIOLOGICAL MARKERS; BIOPSY; CHEMOKINE CXCL9; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LIGANDS; MICE; PREOPERATIVE PERIOD; RISK; TREATMENT OUTCOME;

EID: 77950633336     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.01019.x     Document Type: Note

References (13)

1. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003 197 : 1537.
2. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006 354 : 610.
3. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000 192 : 1515.
4. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002 14 : 562.
5. Zerwes HG, Li J, Kovarik J, et al. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant 2008 8 : 1604.
6. Kwun J, Hazinedaroglu SM, Schadde E, et al. Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients. Am J Transplant 2008 8 : 1593.
7. Halloran PF, Fairchild RL. The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant 2008 8 : 1578.
8. Rotondi M, Rosati A, Buonamano A, et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant 2004 4 : 1466.
9. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005 16 : 1849.
10. Lau A, Turnquist H, Tokita D, Zeevi A, Mazariegos G, Thomon A. "Tolerance" assays: the physician's guide to safe weaning of immunosuppression? Transplant Rev 2006 20 : 208.
11. Rodrigo E, Arias M. A practical approach to immune monitoring in kidney transplantation. Minerva Urol Nefrol 2007 59 : 337.
12. Ashton-Chess J, Soulillou JP, Brouard S. The use of biomarkers in clinical transplant tolerance. Trends Transpl 2007 1 : 46.
13. Sawitzki B, Schlickeiser S, Reinke P, Volk HD. Pretransplant immune risk assessment. Curr Opin Organ Transplant 2009 14 : 650.